Prostate cancer study tests Two-Drug vs. Three-Drug combo
NCT ID NCT06060587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to compare two treatment plans for men with low-volume metastatic prostate cancer that still responds to hormone therapy. One group would receive hormone therapy plus abiraterone, while the other would get those two drugs plus chemotherapy (docetaxel). The goal was to see if adding chemotherapy helps control the cancer longer. However, the study was withdrawn before enrolling any participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?